Severe fever with thrombocytopenia syndrome (SFTS) is an emerging hemorrhagic fever with a high case fatality rate caused by SFTS virus (SFTSV). Effective vaccines and specific therapies for SFTS are urgently sought, and investigation into virus-host cell interactions is expected to contribute to the development of antiviral strategies. In this study, we have developed a pseudotype vesicular stomatitis virus (VSV) bearing the unmodified Gn/Gc glycoproteins (GPs) of SFTSV (SFTSVpv). We have analyzed the host cell entry of this pseudotype virus and native SFTSV. Both SFTSVpv and SFTSV exhibited high infectivity in various mammalian cell lines. The use of lysosomotropic agents indicated that virus entry occurred via pH-dependent endocytosis. SFTSVpv and SFTSV infectivity was neutralized by serial dilutions of convalescent-phase patient sera. Entry of SFTSVpv and growth of SFTSV were increased in Raji cells expressing not only the C-type lectin dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN) but also DC-SIGN-related (DC-SIGNR) and liver and lymph node sinusoidal endothelial cell C-type lectin (LSECtin). 25-Hydroxycholesterol (25HC), a soluble oxysterol metabolite, inhibited the cell entry of SFTSVpv and the membrane fusion of SFTSV. These results indicate that pH-dependent endocytosis of SFTSVpv and SFTSV is enhanced by attachment to certain C-type lectins. SFTSVpv is an appropriate model for the investigation of SFTSV-GP-mediated cell entry and virus neutralization at lower biosafety levels. Furthermore, 25HC may represent a potential antiviral agent against SFTS.
S
evere fever with thrombocytopenia syndrome (SFTS), a newly recognized emerging viral infectious disease, is caused by a novel phlebovirus in the family Bunyaviridae, SFTS virus (SFTSV) (1) (2) (3) . SFTSV can be transmitted to humans by tick bites, causing abrupt high fever, thrombocytopenia, leukopenia, and gastrointestinal symptoms, with a high case fatality rate (4) . SFTSV is a single-stranded negative-sense RNA virus with three genomic segments, L, M, and S. The L segment encodes a viral RNA polymerase, while the M segment encodes the two viral envelope glycoproteins (GPs) Gn and Gc. The S segment is an ambisense RNA encoding a nucleoprotein (NP) and a nonstructural protein (NSs). The Gn and Gc proteins of bunyaviruses are usually localized in the Golgi apparatus, and mature envelope GPs are incorporated into the virus surface. Virus entry into target cells is initiated by the binding of GP to appropriate cell surface receptors. Recently, it was reported that a C-type lectin, dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN), is an initial binding receptor for SFTSV (5) , as was previously reported for other phleboviruses (6) . It was also reported that nonmuscle myosin heavy chain IIA is critical for the cellular entry of SFTSV (7) . Analysis of the initial steps of SFTSV infection, including identification of the entry receptors and the role of viral GP in membrane fusion, may facilitate the development of entry inhibitors. Viral envelope proteins are known to fuse with plasma or endosomal membranes to allow the release of the viral genome. Bunyavirus GPs usually fuse with the endosomal membrane under acidic conditions, causing low-pH-dependent fusion with infected cells (8, 9) . Pseudotype virus systems based on vesicular stomatitis virus (VSV) have been established to allow the virus entry mechanisms to be studied and to identify putative entry receptors (10) . This system allows us not only to investigate the viral envelope protein but also to analyze viral cell entry. Furthermore, this system also allows the life cycle of highly pathogenic viruses to be studied outside biosafety level 3 (BSL-3) or BSL-4 containment. SFTSV is categorized as a BSL-3 pathogen in Japan, and the characteristics of cell entry and virus neutralization have thus far been investigated only through the use of pseudotype viruses bearing the GP of SFTSV (SFTSV-GP) (5) . Although pseudotype viruses bearing specific glycoproteins can authentically mimic the entry process of the native virus, experiments using the native virus will be required to confirm that the entry process is adequately recapitulated by the pseudotype viruses.
The host cell type I interferon (IFN) response is an important mechanism of protection from viral infection (11) . IFN signaling is promoted by the expression of various IFN-stimulated genes (ISGs). Recently, a soluble oxysterol metabolite, 25-hydroxycholesterol (25HC), which is oxidized from cholesterol by an ISG product, cholesterol-25-hydroxylase (Ch25h), was reported to exert broad antiviral activity, inhibiting viral replication and viruscell membrane fusion during virus entry (12, 13) . It was reported that 25HC inhibited the replication of Rift Valley fever virus (RVFV), another member of the Bunyaviridae family, in a dosedependent manner (13) . However, the capacity of 25HC to inhibit other viruses, including SFTSV, remains to be determined.
In this study, we generated a pseudotype VSV bearing the unmodified Gn/Gc glycoproteins of SFTSV (SFTSVpv) and analyzed the host cell entry of this pseudotype virus and the native SFTSV. Furthermore, the role of GP in low-pH-induced cell-to-cell fusion was investigated. We also developed a test of SFTSVpv neutralization using convalescent-phase patient sera. Furthermore, 25HC had potential as an antiviral agent against SFTSV.
MATERIALS AND METHODS
Plasmids, cells, and viruses. The cDNAs of the SFTSV Gn/Gc protein were obtained from SFTSV (HB29 strain) by reverse transcription-PCR (RT-PCR). The Gn/Gc cDNA was cloned into the expression vector pKS336 (14) . The resulting plasmid was designated pKS-SFTSV-GP.
Hamster (BHK and CHO), mouse (NIH 3T3), monkey (Vero and COS7), and human (Huh7, HepG2, HEK 293T, HeLa, A549, Raji, Molt-4, and Jurkat) cell lines were obtained from the American Type Culture Collection (Summit Pharmaceuticals International, Japan). All the cell lines except for Raji, Molt-4, and Jurkat cells were grown in Dulbecco's modified Eagle's medium (DMEM; Sigma-Aldrich, St. Louis, MO) containing 10% heat-inactivated fetal bovine serum (FBS). Raji, Molt-4, and Jurkat cells were grown in RPMI 1640 (Sigma-Aldrich) containing 10% FBS. To establish Jurkat and Raji cell lines that stably express feline CD2 (fCD2), DC-SIGN, DC-SIGN-related (DC-SIGNR), or liver and lymph node sinusoidal endothelial cell C-type lectin (LSECtin), Jurkat and Raji cells were infected with lentiviral vectors encoding fCD2, DC-SIGN, DC-SIGNR, or LSECtin, respectively, as described previously (15) . Expression of fCD2, DC-SIGN, DC-SIGNR, or LSECtin was analyzed by flow cytometry with anti-fCD2 (16), anti-human DC-SIGN and DC-SIGNR (MAB1621; R&D Systems, Inc.), or anti-human LSECtin (SOTO-1; Santa Cruz Biotechnology, Inc.).
SFTSV strain HB29 was amplified on Vero cells and stored at Ϫ80°C until use. The infectious titer was determined by using a focus-forming assay, as described below.
Immunofluorescence and focus-forming assay. For immunofluorescence staining of infected cells or virions, Vero or Huh7 cells transfected with pKS-SFTSV-GP or infected with SFTSV, or the virions, were fixed with acetone-methanol (1:1) at room temperature for 5 min. Fixed cells and virions were stained with mouse monoclonal anti-SFTSV-GP (Immune Technology Corp., New York, NY) and anti-SFTSV-NP (9D3) (27) primary antibodies, respectively. After a 1-h incubation, the cells were rinsed with phosphate-buffered saline (PBS) and incubated with goat anti-mouse Alexa Fluor 488 (Invitrogen). For colocalization analysis, Huh7 cells transfected with pKS-SFTSV-GP were fixed and stained with mouse monoclonal anti-SFTSV-GP or rabbit polyclonal anti-protein disulfide isomerase (PDI) (C81H6; Cell Signaling Technology, Inc., Danvers, MA), anti-RCAS1 (D2B6N; Cell Signaling Technology, Inc.), anti-apoptosisinducing factor (AIF) (D39D2; Cell Signaling Technology, Inc.), antiearly endosome antigen 1 (EEA1) (C45B10; Cell Signaling Technology, Inc.), anti-lysosome-associated membrane protein 1 (LAMP-1) (D2D11; Cell Signaling Technology, Inc.), or anti-claudin-1 (Invitrogen) as primary antibodies and goat anti-mouse Alexa Fluor 488 or chicken antirabbit Alexa Fluor 594 (Invitrogen). After washing with PBS, staining was observed under a fluorescence microscope (BZ-X710; Keyence, Osaka, Japan). For the focus-forming assay, cells infected with SFTSV were cul- tured with 10% FBS-DMEM containing 0.8% methylcellulose for 4 days and then fixed in 10% formalin for 1 h. Cells were washed once with PBS and then incubated with rabbit polyclonal antibody to SFTSV-NP for 1 h. The cells were then treated with secondary antibodies and stained by using 3,3=-diaminobenzidine (DAB) peroxidase stain kit (Nacalai Tesque, Kyoto, Japan), according to the manufacturer's protocols.
Generation of pseudotype viruses. Pseudotype viruses bearing the G protein of VSV (VSVpv), GP of RVFV (RVFVpv), and murine leukemia virus (MLV) envelope protein (MLVpv) were generated as described previously (17, 18) . In brief, HEK 293T cells were grown to 70% confluence on collagen-coated tissue culture plates and then transfected with each of the expression vectors pKS-SFTSV-GP, pKS-RVFV-GP, pCAG-VSV-G, and pFBASALF (which expresses MLV envelope proteins; provided by T. Miyazawa, Kyoto University). After 48 h, the transfected cells were infected with G-complemented VSV⌬G/Luc (*G-VSV⌬G/Luc) (17) at a multiplicity of infection (MOI) of 0.5 per cell. The virus was adsorbed and then extensively washed four times with 10% FBS-DMEM. After 24 h, the culture supernatants containing pseudotype viruses were centrifuged to remove cell debris and stored at Ϫ80°C until use. The infectious titers of the pseudotype viruses were also determined by a focus-forming assay as described previously and recorded as focus-forming units (FFU) (19) . SFTSVpv, RVFVpv, VSVpv, and MLVpv infectivities were assessed by luciferase activity. The relative light units (RLU) of luciferase were determined by using a Bright-Glo luciferase assay system (Promega Corporation, Madison, WI), according to the manufacturer's protocol.
Effects of chemicals on SFTSVpv and SFTSV infectivity.
To examine the effects of endosomal acidification on virus entry, Huh7 and Vero cells were treated with serial dilutions of inhibitors of endosomal acidification, ammonium chloride and bafilomycin A 1 from Streptomyces griseus (Sigma), for 1 h at 37°C. Huh7 cells were then infected with SFTSVpv, RVFVpv, VSVpv, or MLVpv at an MOI of 1. Pseudotype virus infectivity was determined by measuring luciferase activity after incubation at 37°C for 24 h. Vero cells treated with the inhibitors were then infected with SFTSV at an MOI of 0.1. SFTSV infectivity was determined by a focusforming assay as described above.
To examine the effect of 25HC (Sigma) on virus entry and replication, Huh7 and Vero cells were treated with serial dilutions of 25HC for 4 h at 37°C. The cells were then infected with SFTSVpv, RVFVpv, or VSVpv at an MOI of 1. Pseudotype virus infectivity was determined by measuring luciferase activity after incubation at 37°C for 24 h. The cells treated with 25HC were then infected with SFTSV at an MOI of 0.1. Growth of SFTSV in the cells was examined by a focus-forming assay after collection of culture supernatants, continuing for 4 days.
Involvement of C-type lectins in SFTSVpv and SFTSV infection.
To examine the involvement of C-type lectins, such as DC-SIGN, DC-SIGNR, or LSECtin, in virus entry, Jurkat and Raji cells stably expressing DC-SIGN, DC-SIGNR, or LSECtin were infected with SFTSVpv, RVFVpv, or VSVpv at an MOI of 1. Pseudotype virus infectivity was determined by measuring luciferase activities after incubation at 37°C for SFTSVpv, RVFVpv, and 100-fold-diluted VSVpv generated in HEK 293T cells were inoculated into the indicated cell lines. At 24 h postinfection, infectivities of the viruses were determined as RLU. VSVpv without envelope (⌬Gpv) was used as a negative control. The results shown are from three independent assays, with error bars representing standard deviations. (B) Growth of SFTSV in various mammalian cell lines. Cells were infected with SFTSV (HB29 strain) at an MOI of 0.1. After incubation for the indicated number of days, the infectious dose in the supernatants of Vero cells was determined with a focus-forming assay using anti-NP antibody. The results shown are typical of data from two independent experiments. 24 h. Growth of SFTSV in the cells was examined by a focus-forming assay after collection of culture supernatants for 8 days.
Syncytium formation and low-pH treatment. To examine whether syncytium formation of SFTSV-infected cells is induced by low-pH exposure, Vero cells were infected with SFTSV at the indicated MOI. At 48 h postinfection, the cells were rinsed once with PBS and then incubated with citrate-phosphate buffers (0.1 M citric acid, 0.2 M sodium dihydrogen orthophosphate) adjusted to the indicated pH values (pH 7.0, 6.0, and 5.0) for 2 min. The citrate-phosphate buffers were then replaced with 10% FBS-DMEM, and after 4 h, cell fusion within monolayers was observed under a phase-contrast microscope.
To examine the pH dependence of SFTSVpv cell entry, SFTSVpv, RVFVpv, or VSVpv was exposed to citrate-phosphate buffer adjusted to the indicated pH values (pH 7.0, 6.0, 5.0, 4.0, and 3.0) for 2 min. After pH neutralization with a 100ϫ volume of 10% FBS-DMEM, Vero cells were inoculated with each of the viruses. After 24 h at 37°C, residual infectivity was determined by measuring luciferase activities and compared with those of the pseudotype viruses exposed to buffer adjusted to pH 7.0.
Neutralization assays with patient sera. Patient sera were acquired after obtaining informed consent from convalescent patients. All of the protocols and procedures were approved by the research and ethics committees of the National Institute of Infectious Diseases (approval number 531). To examine neutralization of SFTSVpv and SFTSV with convalescent-phase patient serum, SFTSVpv, VSVpv, and SFTSV were preincubated with serially diluted sera of convalescent SFTS patients for 1 h at 37°C. Vero cells were then inoculated with each of the viruses. After 2 h of adsorption at 37°C, the cells were washed with 10% FBS-DMEM, and infectivity was determined after 24 h of incubation at 37°C.
Statistical analysis. The results were expressed as means Ϯ standard deviations. The significance of differences in the means was determined by Student's t test.
RESULTS

Expression and localization of SFTSV-GP.
To examine the expression and localization of SFTSV-GP, Vero and Huh7 cells were infected with SFTSV or transfected with pKS-SFTSV-GP. Robust expression of the GPs was observed in both Vero and Huh7 cells infected with SFTSV or transfected with the plasmid by an immunofluorescence assay (IFA) (Fig. 1A) . GPs in Huh7 cells were mainly colocalized with PDI, RCAS1, and EEA1 but not claudin-1, AIF, and LAMP-1 (Fig. 1B) . These results indicated that SFTSV-GP was mainly localized in intracellular compartments such as the endoplasmic reticulum (ER) and Golgi apparatus but not at the plasma membrane. These results were also observed in infected cells (data not shown).
Infectivity of SFTSVpv and growth of SFTSV in various mammalian cell lines. To examine SFTSVpv infectivity in various mammalian cell lines, the indicated cell lines were inoculated with SFTSVpv, RVFVpv, and VSVpv. Most cell lines, excluding lymphocytes, were susceptible to SFTSVpv and RVFVpv infection ( Fig. 2A) . Among the cell lines examined, BHK, Vero, COS7, HepG2, and Huh7 cells were highly susceptible to SFTSVpv infection, while CHO, HEK 293T, and A549 cells were less susceptible. NIH 3T3 and HeLa cells, which were previously reported to be resistant to SFTSVpv entry (5), were moderately susceptible to SFTSVpv infection, compared with SFTSVpv infection of lymphocytes. To examine SFTSV growth, the cell lines were inoculated with SFTSV (Fig. 2B) . SFTSV replicated well in Vero and Huh7 cells for 5 days, while it did not replicate in CHO or BHK cells during the same time period. The replication of SFTSV in HeLa cells was slightly increased in this study, in contrast to previous reports (5, 7).
Entry pathways. Previous studies indicated that pseudotype virus bearing the SFTSV glycoprotein was inhibited by treatment with inhibitors of vacuolar acidification, such as ammonium chloride and bafilomycin A 1 , suggesting that the pseudotype virus enters target cells via pH-dependent endocytosis (5). To examine the entry pathway of SFTSV and pseudotype viruses, Huh7 cells were pretreated with various concentrations of ammonium chloride or bafilomycin A 1 and then inoculated with SFTSVpv, RVFVpv, VSVpv, MLVpv, or SFTSV. Neither ammonium chloride nor bafilomycin A 1 treatment affected the infectivity of MLVpv, but SFTSVpv, RVFVpv, and VSVpv infectivity decreased in a dosedependent manner (Fig. 3A) . In contrast, the infectivity of SFTSV was dose-dependently inhibited by treatment with ammonium chloride and bafilomycin A 1 (Fig. 3B) .
Neutralization assays. The capacities of the sera collected from convalescent SFTS patients to neutralize SFTSVpv and SFTSV were compared. Sera from convalescent SFTS patients particularly neutralized both SFTSVpv and SFTSV in a dilution-dependent manner, whereas no neutralization of VSVpv infection was observed (Fig. 4) . The infectivity of SFTSVpv was completely neutralized at low dilutions of sera from convalescent SFTS patients. SFTSVpv and SFTSV infection was also neutralized by all sera from convalescent SFTS patients (data not shown).
Involvement of C-type lectins in SFTSVpv and SFTSV infection. C-type lectins such as DC-SIGN were reported previously to be involved in cell entry of various viruses (20) . SFTSVpv was recently reported to use DC-SIGN as a receptor for host cell entry (5). The involvement of several C-type lectins, DC-SIGN, DC-SIGNR, and LSECtin, in SFTSVpv and SFTSV infection was evaluated. Jurkat and Raji cells were transfected with lentiviral vectors encoding fCD2, DC-SIGN, DC-SIGNR, or LSECtin, and these molecules were expressed on the cell surface (Fig. 5A) . The expression of DC-SIGN, DC-SIGNR, and LSECtin in Jurkat or Raji cells drastically increased SFTSVpv infection and moderately increased RVFVpv infection, whereas no significant increase in VSVpv infection was observed (Fig. 5B) . To confirm the involvement of the C-type lectins, the growth of SFTSV in Raji cells stably expressing each molecule was examined. The growth of SFTSV was increased by ϳ100-fold within 8 days in all Raji cells expressing each molecule (Fig. 5C) .
Syncytium formation in SFTSV-infected cells exposed to low pH. To examine the formation of SFTSV-infected cell syncytia, Vero cells were infected with SFTSV and cultured for 48 h. The cells were then treated with the buffer at the indicated pH for 2 min. The infectivity of SFTSV was confirmed by an immunofluorescence assay with anti-SFTSV-NP or -GP (data not shown). Syncytia in SFTSV-infected cells were observed within 1 h after treatment with buffers below pH 6.0 (Fig. 6A) . Previously, low pH was reported to alter the conformation of arenaviral GP in the absence of cellular receptors, abolishing viral infectivity (21) . To examine the effect of low-pH exposure on SFTSVpv infection, the viruses were treated with buffer at the indicated pH before infec- tion. The infectivity of SFTSVpv and RVFVpv was abolished by low-pH treatment (Fig. 6B) , indicating that the SFTSV-GP conformation may be altered under low-pH conditions in the absence of host factors, such as receptor molecules.
Effect of 25HC on SFTSV infection. It was recently reported that 25HC broadly inhibited virus entry or replication steps (12, 13) . We investigated whether SFTSV entry was inhibited by 25HC by examining the infectivity of SFTSVpv and the growth of SFTSV in Vero and Huh7 cells in the presence of 25HC. SFTSVpv infection and the growth of SFTSV were particularly inhibited by 25HC in a dose-dependent manner in both Vero and Huh7 cells (Fig. 7A  and B) . These results indicated that 25HC mainly affected SFTSV cell entry. We further examined whether the inhibitory effects of 25HC targeted SFTSV fusion. Syncytium formation of SFTSVinfected cells at low pH was inhibited by 25HC in a dose-dependent manner (Fig. 7C and D) . The expression of SFTSV-GP and -NP was clearly observed in all cells treated with various concentrations of 25HC by immunofluorescence staining (Fig. 7C) , and SFTSV-infected cell syncytium formation was also inhibited even by a 3-h exposure to 25HC (data not shown), suggesting that the expression of SFTSV-GP was not altered. Finally, we examined the effects of 25HC on the binding and internalization of SFTSV by immunofluorescence staining of the virions. 25HC had no significant effect on binding and internalization (Fig. 7E) . Taken together, these results suggest that 25HC acts potently after the internalization of SFTSV.
DISCUSSION
Currently, SFTSV has been identified only in China, Japan, and South Korea. However, Heartland virus, Bhanja virus, and other phleboviruses, which cause diseases similar to SFTS, have been isolated previously (22, 23) . Understanding the life cycles of these viruses may inform the development of important antiviral strategies. In particular, understanding the initial steps of viral infection, binding, penetration, and fusion, is necessary for the specific development of entry inhibitors to prevent virus spread.
Generally, VSV assembles and buds from the plasma membrane. Therefore, viral GPs presented on the cell surface are efficiently incorporated into the virions. The GP of SFTSV and those of other bunyaviruses, including RVFV, are mainly localized in intracellular compartments, such as the ER and Golgi apparatus of the target cells, but not at the plasma membrane ( Fig. 1) (24) . Although incorporation of the GP into SFTSVpv particles could not be analyzed because the antibodies required for immunoblot analysis are not yet available, SFTSVpv and RVFVpv were able to infect various types of mammalian cell lines (Fig. 2A) . Furthermore, SFTSVpv was neutralized by SFTS patient sera. These results suggest that SFTSVpv particles incorporated GP onto the virion surface and that GP was involved in virus entry. Further studies will be required to clarify the mechanisms by which SFTSV GP is incorporated into VSV particles and the role of SFTSV GP glycosylation in cell entry.
Previous studies demonstrated that HeLa cells were not susceptible to SFTSVpv and SFTSV infection (5, 7) . In this study, HeLa cells were weakly susceptible to infection with these viruses ( Fig. 2A and B) . Furthermore, COS7 cells were highly susceptible to infection by SFTSVpv, consistent with data from a previous report (5) . COS7 cells were also moderately susceptible, in contrast data from to another previous report (7) . Further studies will be needed to clarify these discrepancies and to identify the viral Relative infectivity of SFTSVpv after exposure to buffer at the indicated pH. SFTSVpv, RVFVpv, and VSVpv were exposed to buffer at the indicated pH for 2 min. After neutralization with DMEM containing 10% FCS, the remaining infectivities of the pseudotype viruses to Vero cells were measured. Infectivities of SFTSVpv were determined by measuring luciferase activities at 24 h postinfection. The results shown are from three independent assays, with error bars representing standard deviations. *, P Ͻ 0.05; **, P Ͻ 0.01. entry receptor(s) and host factor(s) essential for virus growth. Although it is likely that lymphocytes are primary target cells of SFTSV infection in humans, lymphocyte cell lines were not very susceptible to SFTSVpv and SFTSV infection. However, further work will be required to assess the susceptibility of primary human lymphocytes.
C-type lectins, such as DC-SIGN and DC-SIGNR, are utilized as an initial binding receptor for various types of viruses. We observed that not only DC-SIGN but also DC-SIGNR and LSECtin were involved in the entry of SFTSV. Furthermore, although SFTSV did not grow in Raji cells, when the expression of these C-type lectins was induced, they became susceptible to SFTSV infection (Fig. 5B) . The expression of C-type lectins enhanced the susceptibilities of Jurkat and Raji cells to SFTSVpv more than those to RVFVpv or VSVpv. C-type lectins appear to play a critical role in the binding of viruses to nonsusceptible cells, acting as enhancing binding molecules. However, they may have a minor or no role in the binding of viruses to target cells that express other major binding and/or entry receptors. VSVpv can infect Jurkat and Raji cells well; therefore, no enhancement of infectivity would be observed in C-type lectin-expressing cells. Cell-cell fusion is generally induced when viral GP is present at the plasma membrane. Cell fusion occurred in cells infected with SFTSV or RVFV despite the fact that GP was present mainly in the intracellular compartment and not on the plasma membrane (8) . Perhaps, the overexpression of viral GP in infected cells breaks its retention in the ER or Golgi apparatus; therefore, a small portion of the GP leaks onto the plasma membrane at a level undetectable by an IFA. Results of cell fusion in cells transfected with expression plasmids of SFTSV-GP were also obtained (data not shown).
Cholesterol is one of the most abundant lipids in the plasma membrane. The distribution of cholesterol, such as cholesterolrich microdomains, namely, rafts, in the plasma membrane affects the entry, replication, and budding of many viruses. The oxysterol 25HC is a metabolite of cholesterol produced and secreted by macrophages and has multiple effects on lipid metabolism. Recently, 25HC was reported to be a potent antiviral mediator against various kinds of viruses (25, 26) . In this study, the addition of 25HC drastically inhibited SFTSV growth, particularly the inhibition of virus entry ( Fig. 7A and B) . 25HC might inhibit SFTSV fusion ( Fig. 7C to E) . Previous studies demonstrated that 25HC broadly inhibited viral membrane fusion, which was not specific to particular structural classes of fusion peptides, suggesting the involvement of more basic fusion processes (13) . Cell-cell fusion of Vero cells expressing Nipah virus F and G was inhibited by 25HC under pH-neutral conditions (13) . The cell fusion of SFTSV-infected cells may occur via a mechanism similar to that of Nipah virus. If recombinant SFTSV encoding a color marker gene could be constructed, the effects of 25HC on fusion events could be clearly observed in real time. The treatment of mice with high doses of 25HC decreased the infection and replication of some viruses, and the capacity of virus growth was increased in Ch25h-deficient mice (13) . Further in vivo experiments will be needed to verify the inhibitory effect of 25HC.
In conclusion, we analyzed the mechanisms of SFTSV entry and fusion using native and pseudotype viruses possessing the SFTSV envelope proteins. We demonstrated for the first time that the production of SFTSV and membrane fusion of SFTSV-GP were inhibited by 25HC. SFTSVpv is useful not only for analyses of SFTSV cell entry but also for development of a neutralization test for the diagnosis of SFTS at lower biosafety levels. 25HC could be considered a therapeutic SFTSV inhibitor.
